Demonstrates improved hemoglobin levels with pegcetacoplan in paroxysmal nocturnal hemoglobinuria, indicating clinical benefits over eculizumab.
Pegcetacoplan, the first approved proximal complement C3 inhibitor, showed superiority to eculizumab in improving hemoglobin levels and clinical outcomes in the phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria (PNH) and inadequate response to eculizumab.
No takes yet. Share an insight, caveat, or question.
Nishimori et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: